Cancer in the bloodstream can be just as aggressive as cancers that form solid masses. Fortunately, the long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease, and multiple myeloma—the various cancers associated with blood and plasma.
Intensive studies within the cutting-edge HM program use clinical research to target and treat the two major types of blood cells (myeloid and lymphoid) that generate malignant blood cancer.
To expand opportunities for cures that use a patient’s own (autologous) stem and bone marrow cells as well as donor (allogenic) cells and marrow transplantation
To improve cures by increasing our understanding of malignant stem cells in blood cancers
To develop new, non-transplant, experimental therapies for blood cancers
By bringing together clinical and basic scientists in dynamic ways, City of Hope’s clinical transplant studies are enriched by studies into individual diseases (leukemia, myelomas, lymphomas, and Hodgkin’s disease). The result aids a comprehensive attack on cancer in all of its forms—in the bloodstream and beyond.
Program Co-Leaders Stephen J. Forman
, M.D. and Wing-Chung (John) Chan
, M.D. lead a team
of prominent clinical, translational and basic scientific researchers with a broad spectrum of expertise who are committed toward a common goal. Because of them, City of Hope is proud to be in the forefront of advancement in hematologic malignancies.